IMMUNE MONITORING OF DENDRITIC CELL-BASED CANCER VACCINE IN GLIOBLASTOMA PATIENTS

Authors:

Abstract:

The purpose of the study was to define the most informative immunological criteria for assessing the immunotherapy efficacy applying dendritic cell-based cancer vaccine in glioblastoma patients. Dendritic cell-based cancer vaccine immunotherapy does not affect significantly the count of the major populations of peripheral blood cells (T-, B- and NK-cells). The most significant changes in dendritic cell-based cancer vaccine glioblastoma patients were evident in subpopulations of CD3+HLA+- and CD38+- activated lymphocytes as well as suppressor cells (MDSC and Т-reg (CD4+25+127low)). According to ROC analysis the sufficient sensitivity and specificity were estimated for 3 biomarkers, namely the relative count of activated CD38+- and CD3+HLA+- lymphocytes and Т-reg cells. The threshold levels for the counts of these cells have been determined. The obtained results allow recommending these indices as the immunological criteria for assessing the efficacy of dendritic cell-based cancer vaccine in the treatment of glioblastoma.

Keywords:

oncology immunotherapy dendritic cells immunological criteria

References:

1. Fedorenko ZP, Michailovich YYo, Goulak LO, Gorokh YL, Ryzhov AYu, Soumkina OV, et al. Rak v Ukrayini, 2019–2020. Byuleten Natsionalnoho kantser-reyestru Ukrayiny, No. 22. [in Ukranian]
2. Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3(21): e122264.
3. Erhart F, Buchroithner J, Reitermaier R, Fischhuber K, Klingenbrunner S, Sloma I, et al. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathologica Communications. 2018; 6:135. doi.org/10.1186/s40478-018-0621-2.
4. Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, et al. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis. 2018;10(Suppl 13):1564-S1580.
5. Hu-Lieskovan S, Bhaumik S, Dhodapkar K. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. Journal for ImmunoTherapy of Cancer. 2020;8:e000705. doi:10.1136/jitc-2020-000705.
6. Jan CI, Tsai WC, Harn HJ, Shyu WC, Liu MC, Lu HM, et al. Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme. Front. Immunol. 2018; 9:727. https://doi.org/10.3389/fimmu.2018.00727.
7. Mohme M, Schliffke S, Maire CL, Runger A, Glau L, Mende KC, et al. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res. 2018; 24(17): 4187-4200.
8. Mostafa H, Pala A, Högel J, Hlavac M, Dietrich EM. Immune phenotypes predict survival in patients with glioblastoma multiforme. Journal of Hematology & Oncology. 2016; 9:77.
9. Srivastava S, Jackson C, Kim T, Choi J, Lim M. A Characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers. 2019; 11: 537; doi:10.3390/cancers11040537.
10. Tcyganov E, Mastio J, Chen E, Gabrilovich D. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018; 51: 76-82. doi: 10.1016/j.coi.2018.03.009.
11. Weenink B, French PJ, Smitt PS, Debets R, Geurts M. Immunotherapy in glioblastoma: current shortcomings and future perspectives. Cancers. 2020; 12: 751; doi:10.3390/cancers12030751.

Publication:

«World of Medicine and Biology» Vol. 17 No. 77 (2021) , с. 152-157
УДК 616-006.484.04:615.277.3

DOI:

https://doi.org/10.26724/2079-8334-2021-3-77-152-157